Advanced search
Publication Cover
OncoImmunology Volume 7, 2018 - Issue 9
Submit an article Journal homepage
1,749
Views
19
CrossRef citations to date
0
Altmetric
Original Research

Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells

Todd A. BraciakDepartment of Hematology and Oncology, Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Munich, GermanyView further author information
,
Claudia C. RoskopfDepartment of Hematology and Oncology, Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Munich, GermanyView further author information
,
Sarah WildenhainDepartment of Biochemistry and Gene Center, Ludwig-Maximilians-Universität, Munich, GermanyView further author information
,
Nadja C. FennDepartment of Biochemistry and Gene Center, Ludwig-Maximilians-Universität, Munich, GermanyView further author information
,
Christian B. SchillerDepartment of Biochemistry and Gene Center, Ludwig-Maximilians-Universität, Munich, GermanyView further author information
,
Ingo A. SchubertDepartment of Biology, University of Erlangen-Nuremberg, Erlangen, GermanyView further author information
,
Uwe JacobWestend Innovation, Munich, GermanyView further author information
,
Annemarie HoneggerDepartment of Biochemistry, University of Zurich, Zurich, SwitzerlandORCID Iconhttp://orcid.org/0000-0002-3378-3967View further author information
ORCID Icon,
Christina KrupkaDepartment of Hematology and Oncology, Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Munich, Germany;Laboratory of Translational Cancer Immunol ogy, Gene Center of the LMU Munich, Munich, GermanyView further author information
,
Marion SubkleweDepartment of Hematology and Oncology, Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Munich, Germany;Laboratory of Translational Cancer Immunol ogy, Gene Center of the LMU Munich, Munich, GermanyView further author information
,
Karsten SpiekermannDepartment of Hematology and Oncology, Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Munich, GermanyView further author information
,
Karl-Peter HopfnerDepartment of Biochemistry and Gene Center, Ludwig-Maximilians-Universität, Munich, GermanyView further author information
,
Georg H. FeyDepartment of Biology, University of Erlangen-Nuremberg, Erlangen, GermanyView further author information
,
Michael AignerDepartment of Internal Medicine 5 - Hematology/Oncology, University of Erlangen-Nuremberg, Erlangen, GermanyView further author information
,
Stefan KrauseDepartment of Internal Medicine 5 - Hematology/Oncology, University of Erlangen-Nuremberg, Erlangen, GermanyView further author information
,
Andreas MackensenDepartment of Internal Medicine 5 - Hematology/Oncology, University of Erlangen-Nuremberg, Erlangen, GermanyView further author information
&
Fuat S. OduncuDepartment of Hematology and Oncology, Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Munich, GermanyCorrespondence[email protected]
View further author information
 show all
Article: e1472195 | Received 20 Feb 2018, Accepted 29 Apr 2018, Published online: 30 Jul 2018

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Antonio Tapia-Galisteo, Íñigo Sánchez Rodríguez, Oscar Aguilar-Sopeña, Seandean Lykke Harwood, Javier Narbona, Mariola Ferreras Gutierrez, Rocío Navarro, Laura Martín-García, Cesáreo Corbacho, Marta Compte, Javier Lacadena, Francisco J. Blanco, Patrick Chames, Pedro Roda-Navarro, Luis Álvarez-Vallina & Laura Sanz. (2022) Trispecific T-cell engagers for dual tumor-targeting of colorectal cancer. OncoImmunology 11:1.
Read now
Xavier Thomas, Mohamed Elhamri, Alexandre Deloire & Maël Heiblig. (2022) Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials. Expert Opinion on Emerging Drugs 27:2, pages 169-185.
Read now

Articles from other publishers (17)

Antonio Tapia-Galisteo, Luis Álvarez-Vallina & Laura Sanz. (2023) Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies. Journal of Hematology & Oncology 16:1.
Crossref
Pooya Farhangnia, Ali-Akbar Delbandi, Maryam Sadri & Mahzad Akbarpour. 2022. Handbook of Cancer and Immunology. Handbook of Cancer and Immunology 1 46 .
Yaping Sun & Jian Xu. (2022) Emerging Antibodies in Cancer Therapy. Advanced NanoBiomed Research 3:1.
Crossref
Daniela Damiani & Mario Tiribelli. (2022) Present and Future Role of Immune Targets in Acute Myeloid Leukemia. Cancers 15:1, pages 253.
Crossref
Jingjing Liu, Jiayin Tong & Haiping Yang. (2022) Targeting CD33 for acute myeloid leukemia therapy. BMC Cancer 22:1.
Crossref
Oren Pasvolsky, May Daher, Gheath Alatrash, David Marin, Naval Daver, Farhad Ravandi, Katy Rezvani, Elizabeth Shpall & Partow Kebriaei. (2022) CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. Frontiers in Oncology 11.
Crossref
Fabiana Perna, Manuel R. Espinoza-Gutarra, Giuseppe Bombaci, Sherif S. Farag & Jennifer E. Schwartz. 2022. Cancer Immunotherapies. Cancer Immunotherapies 225 254 .
Hongtao Liu. (2021) Emerging agents and regimens for AML. Journal of Hematology & Oncology 14:1.
Crossref
Raynier Devillier, Anne-Sophie Chrétien, Thomas Pagliardini, Nassim Salem, Didier Blaise & Daniel Olive. (2021) Mechanisms of NK cell dysfunction in the tumor microenvironment and current clinical approaches to harness NK cell potential for immunotherapy. Journal of Leukocyte Biology 109:6, pages 1071-1088.
Crossref
Alessandro Isidori, Claudio Cerchione, Naval Daver, Courtney DiNardo, Guillermo Garcia-Manero, Marina Konopleva, Elias Jabbour, Farhad Ravandi, Tapan Kadia, Adolfo de la Fuente Burguera, Alessandra Romano, Federica Loscocco, Giuseppe Visani, Giovanni Martinelli, Hagop Kantarjian & Antonio Curti. (2021) Immunotherapy in Acute Myeloid Leukemia: Where We Stand. Frontiers in Oncology 11.
Crossref
Zheng Tian, Ming Liu, Ya Zhang & Xin Wang. (2021) Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. Journal of Hematology & Oncology 14:1.
Crossref
Fadi Haddad & Naval Daver. 2021. Immunotherapy. Immunotherapy 273 295 .
Xavier Roussel, Etienne Daguindau, Ana Berceanu, Yohan Desbrosses, Walid Warda, Mathieu Neto da Rocha, Rim Trad, Eric Deconinck, Marina Deschamps & Christophe Ferrand. (2020) Acute Myeloid Leukemia: From Biology to Clinical Practices Through Development and Pre-Clinical Therapeutics. Frontiers in Oncology 10.
Crossref
Hanadi El Achi, Edouard Dupont, Shilpa Paul & Joseph D. Khoury. (2020) CD123 as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies. Cancers 12:11, pages 3087.
Crossref
Lia Walcher, Ann-Kathrin Kistenmacher, Huizhen Suo, Reni Kitte, Sarah Dluczek, Alexander Strauß, André-René Blaudszun, Tetyana Yevsa, Stephan Fricke & Uta Kossatz-Boehlert. (2020) Cancer Stem Cells—Origins and Biomarkers: Perspectives for Targeted Personalized Therapies. Frontiers in Immunology 11.
Crossref
Testa, Pelosi & Castelli. (2019) CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. Cancers 11:9, pages 1358.
Crossref
Shili Sun, Huixi Zou, Lin Li, Qi Liu, Ning Ding, Lili Zeng, Hui Li & Shengjun Mao. (2019) CD123/CD33 dual-antibody modified liposomes effectively target acute myeloid leukemia cells and reduce antigen-negative escape. International Journal of Pharmaceutics 568, pages 118518.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.